Scientists have devised a novel drug combination that could treat a particularly deadly form of leukemia, known as blast crisis (BC) chronic myeloid leukemia (CML). The team has also developed strategies that may identify patients with early stage or chronic phase (CP) CML who are at increased risk of developing BC, and potentially preventing disease progression.